Press Release: Esperance : Esperance Reports Positive EP-100 Phase ll Results in Ovarian Cancer at 2015 ASCO Annual Meeting

BATON ROUGE, La., June 1, 2015 /PRNewswire/ -- Esperance Pharmaceuticals Inc. today reported positive results from a Phase II trial of lead candidate EP-100 in ovarian cancer patients resistant to paclitaxel. EP-100 is a targeted membrane-disrupting peptide designed to seek and destroy...